LAUREL DUBA: Open Payments
NPI 1669901765 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,365 in 74 payments from 21 companies in 2025. Trend: 2023 $1,102 · 2024 $631 · 2025 $1,365
Food & beverage: $1,365
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 16 | $248 |
| Novo Nordisk Inc | 8 | $145 |
| Lilly USA, LLC | 10 | $136 |
| Astellas Pharma US Inc | 4 | $134 |
| Otsuka America Pharmaceutical, Inc. | 6 | $133 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $93 |
| ABBVIE INC. | 4 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| Amgen Inc. | 2 | $36 |
Products named: NURTEC ODT, REXULTI, Veozah, CAPLYTA, MOUNJARO, VRAYLAR, Wegovy, TRINTELLIX.
Industry payments across NE — which companies pay providers there.
